The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $14,690 firm fixed-price purchase order to Adaptive Biotechnologies Corporation (doing business as Adaptive) for ImmunoSEQ sequencing services. The contract has an ultimate completion date of December 20, 2024. Adaptive is a commercial provider of immune-driven medicine services and products, and has previously received federal contracts and grants from the Department of Health and Human Services (HHS), Department of Veterans Affairs (VA), and Defense Health Agency to provide specialized testing and genomic sequencing services. This award does not have a set-aside designation.
Generated 9/24/24, 9:31 AM